Tobramycin Sulfate

CHEMBL3989564 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1425.4 g/mol
LogP
Phase
4

A sulfate salt form of tobramycin with the same therapeutic properties. This aminoglycoside antibiotic is used to treat serious bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa, including infections of the lungs in cystic fibrosis patients (via inhalation), eye infections (as drops), and severe systemic infections (by injection).

Berat Molekul

1425,4000 g/mol

TPSA

951,00 Ų

Area Terapeutik

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O.NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O

InChI

InChI=1S/2C18H37N5O9.5H2O4S/c2*19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18;5*1-5(2,3)4/h2*5-18,24-28H,1-4,19-23H2;5*(H2,1,2,3,4)/t2*5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+;;;;;/m00...../s1

Molecular Formula

C36H84N10O38S5

HBD / HBA

30 / 48

Ikatan yang Dapat Dirotasi

12

Atom Berat

89

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A sulfate salt form of tobramycin with the same therapeutic properties. This aminoglycoside antibiotic is used to treat serious bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa, including infections of the lungs in cystic fibrosis patients (via inhalation), eye infections (as drops), and severe systemic infections (by injection).

Yes, Tobramycin Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989564. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 11954252. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.